Analysis of ALS patient tissues and registry
Analysis of Human ALS Tissues and Registry of ALS Patients
This study is trying to gather information from people with ALS to better understand the disease and find new ways to treat it.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | University of Illinois at Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT05067179 on ClinicalTrials.gov |
What this trial studies
This research focuses on understanding Amyotrophic Lateral Sclerosis (ALS) by collecting data from patients through physical examinations, electrodiagnostic testing, and MRI scans. Patients will consent to have their information entered into a database to monitor disease progression and contribute to research efforts. Additionally, a separate consent will allow for postmortem tissue collection to facilitate in-depth cellular and molecular analyses. The goal is to identify reliable markers of disease progression and potential treatment avenues.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with an established diagnosis of ALS who can provide informed consent.
Not a fit: Patients under 18 or those without a diagnosis of ALS will not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to a better understanding of ALS and the development of effective treatments.
How similar studies have performed: While there have been various studies on ALS, this approach of combining premortem and postmortem analyses is relatively novel and aims to fill significant gaps in understanding the disease.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over the age of 18 * Established diagnosis of ALS * Able and willing to give written informed consent and must authorize release and use of protected health information Exclusion Criteria: * Patients below the age of 18 * No diagnosis of ALS
Where this trial is running
Chicago, Illinois
- University of Illinois at Chicago — Chicago, Illinois, United States (Recruiting)
Study contacts
- Principal investigator: Jeffrey Loeb, MD — University of Illinois at Chicago
- Study coordinator: Ayo Fasawe
- Email: afasawe@ilstu.edu
- Phone: 312-413-7908
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.